Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins.
about
The use of cephalosporins for gonorrhea: the impending problem of resistancePhase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infectionsOnce-daily cefazolin and probenecid for skin and soft tissue infectionsThe pharmacokinetics and pharmacodynamics of the carbapanemes: focus on doripenemBacterial temporal dynamics enable optimal design of antibiotic treatmentPopulation Pharmacokinetics and Dosing Regimen Optimization of Meropenem in Cerebrospinal Fluid and Plasma in Patients with Meningitis after NeurosurgeryClarithromycin: pharmacokinetic and pharmacodynamic interrelationships and dosage regimen.Pharmacodynamics of cefepime alone and in combination with various antimicrobials against methicillin-resistant Staphylococcus aureus in an in vitro pharmacodynamic infection model.Identification of optimal renal dosage adjustments for traditional and extended-infusion piperacillin-tazobactam dosing regimens in hospitalized patients.In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa.Impact of renal function on the pharmacokinetics and safety of ceftolozane-tazobactam.Cefiderocol, a Siderophore Cephalosporin for Gram-Negative Bacterial Infections: Pharmacokinetics and Safety in Subjects With Renal ImpairmentAntibiotic resistance: a current perspective.In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations.Pharmacokinetics of meropenem in critically ill patients with acute renal failure treated by continuous hemodiafiltration.Antimicrobial resistance in gram-positive bacteria: the myth of the MIC. Minimum inhibitory concentration.Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection.Evaluation by monte carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers.Altered pharmacokinetics of piperacillin in febrile neutropenic patients with hematological malignancyPharmacokinetics of prophylactic cefazolin in parturients undergoing cesarean delivery.Pharmacodynamics of cefquinome in a neutropenic mouse thigh model of Staphylococcus aureus infectionPharmacokinetics and pharmacodynamics of imipenem during continuous renal replacement therapy in critically ill patients.Prospective monitoring of cefepime in intensive care unit adult patientsNovel oral cephalosporins.Evaluation of several dosing regimens of cefepime, with various simulations of renal function, against clinical isolates of Pseudomonas aeruginosa in a pharmacodynamic infection model.Pharmacodynamic assessment of cefprozil against Streptococcus pneumoniae: implications for breakpoint determinations.In vitro and in vivo activities of amikacin, cefepime, amikacin plus cefepime, and imipenem against an SHV-5 extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strain.Pharmacokinetics of cefepime during continuous renal replacement therapy in critically ill patients.Medical resource utilization among patients with ventilator-associated pneumonia: pooled analysis of randomized studies of doripenem versus comparatorsIs the standard dose of amoxicillin-clavulanic acid sufficient?Pharmacokinetic/pharmacodynamic investigation of colistin against Pseudomonas aeruginosa using an in vitro model.Determination of the in vivo pharmacodynamic profile of cefepime against extended-spectrum-beta-lactamase-producing Escherichia coli at various inocula.Determination of antibiotic effect in an in vitro pharmacodynamic model: comparison with an established animal model of infectionCurrent treatment of sepsis and endotoxaemia.Antimicrobial breakpoints for gram-negative aerobic bacteria based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulationEffect of a single percutaneous abscess drainage puncture and imipenem therapy, alone or in combination, in treatment of mixed-infection abscesses in mice.In vivo activity of cefquinome against Escherichia coli in the thighs of neutropenic miceImpact of MIC range for Pseudomonas aeruginosa and Streptococcus pneumoniae on the ceftolozane in vivo pharmacokinetic/pharmacodynamic target.In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum β-lactamases, in the thighs of neutropenic mice.Nonlinear pharmacokinetics of piperacillin in healthy volunteers--implications for optimal dosage regimens
P2860
Q24656750-0F57B388-852F-4DB4-BD03-E92F2F3D3507Q24672937-12C8A2CE-1BD1-49A3-931E-D46AC56C21D7Q28245769-7C55804F-E0B3-4692-9966-989B03B36837Q28289744-3DA8FE34-DE1C-4076-8867-DE12BD72F0D4Q28546654-241E4951-435B-43EC-8E55-2A0BF0E27D1FQ30370090-3C1BAD29-E841-45A2-BCD8-DD981BFE80ACQ33541485-3D4AB9E8-86B3-4766-8862-48D468B727B6Q33555775-7B7D28E2-1659-4CD6-84EA-0106FEA9C189Q33559047-A6F686F0-B5CA-45A3-901C-917B76407168Q33559139-5F535C91-C423-430B-965C-C42C40149A2EQ33623078-136A4385-E9BB-4BF1-AF91-677F86CAB1B0Q33625994-239BF394-DB22-494F-933D-BF943EB39196Q33693954-BFD22448-71F3-461A-AC98-0FF8F4AC8B5CQ33697003-9CA49F75-C88E-450B-8675-6C874611C419Q33697176-51ECD21D-6FAF-482F-8511-C9310DB8D0F2Q33717162-441B4AD2-7625-4E6C-8C7D-FB751B8C8735Q33722108-CF2F57DF-DAD8-40D4-9ABA-53D61680DFEDQ33770046-00D0DAF4-3427-43A1-A958-4965737402FBQ33797868-F6ED22E5-EA47-4E16-AF02-2A799853D906Q33797920-A3E735A6-D7CE-4367-891E-5114AD51B821Q33797936-70DB17D2-796E-4F7C-B92C-8D2794343F72Q33836550-E3564D07-BBA0-4F06-B6CA-4D9F32214B49Q33919165-A4910030-C5E0-45A3-9FFD-F248F48EDFBDQ33924031-375A9F18-0D9C-45A0-8D24-5A488FBA750EQ33975896-66B28367-580A-4EF2-937F-B6F85AA5C4A8Q33979445-69F652C3-A904-47F6-91AA-1B059B806C7BQ33981993-42F74311-3F11-4A73-AC77-8C4A1D4B04ADQ33983364-F2B09A17-5223-46B6-9028-1FA5E7098A79Q34026818-9DD72BE4-BB60-4BBB-B263-91021423D0ADQ34030839-3B40CE07-EE8C-47FE-BF71-ED4C12317D07Q34108660-60BAB292-4BC8-45BC-9055-A9C9E1D645FEQ34139332-60E5D3AC-35A8-434B-BC2F-B0D0E29E970CQ34141627-F29E22B5-C8F8-4038-9604-1843666654D5Q34181936-A2B3FB47-0F7A-4880-B85F-54965ECD3CDFQ34188814-9A8B0F0A-24EC-46DB-948B-B69AFFF507E8Q34252679-14F280B6-1F08-4123-83F4-604FA31C1E23Q34299028-DF2C0332-5542-4E96-917A-E513A48F573FQ34299064-F3485714-5948-4A3F-A24D-AD764B683E00Q34320027-6D606EE8-E633-42EF-9635-F306622ADD25Q34381321-2772AFDD-42E6-4184-B265-1F38C1E030D1
P2860
Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh
1995年學術文章
@zh-hant
name
Interrelationship between phar ...... broad-spectrum cephalosporins.
@en
type
label
Interrelationship between phar ...... broad-spectrum cephalosporins.
@en
prefLabel
Interrelationship between phar ...... broad-spectrum cephalosporins.
@en
P1476
Interrelationship between phar ...... broad-spectrum cephalosporins.
@en
P2093
P356
10.1016/0732-8893(95)00053-D
P577
1995-05-01T00:00:00Z